2) TBMD TMTI - Biological Warfare Defense Therapeutics
Abstract
Biological Warfare (BW) defense therapeutics mitigate and reverse the effects of known and emerging viral, bacterial, and toxin biological warfare threats in symptomatic warfighters diagnosed with BW disease. Biomedical research is focused on nonclinical and early clinical development of therapeutic countermeasures against known and emerging viral, bacterial, and toxin BW threats for which Food and Drug Administration (FDA)-approved therapeutics are limited or lacking. Broad-spectrum therapeutic candidates that are shown to be both safe and efficacious against BW threats will advance for further clinical evaluation and can be accelerated for use against emerging infectious diseases during an outbreak. Refinement of appropriate animal models in which to evaluate therapeutic candidates is also included. Projects leverage interagency and commercial sector investments to accelerate development and reduce costs.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2024
- Source ID
- 2e0e4ca7a3a5aaa5866a7f0dea6fa9f7